1. Sacks B, Arnold M, Bakris G L, Bruns D E, Horvath A R, Guidelines and Recommendations for Laboratory-Analysis in the Diagnosis and Management of Diabetes-Mellitus. J Clin Chem 2012;34:61-99. [DOI:10.2337/dc11-9998]

2. Ragnar Hanas, Type 1 Diabetes in Children Adolescents and Young Adults: How to Become an Expert on Your Own Diabetes. Class Health 2010; 6:595-7.

3. Charles Rajesh Kumar.J, Mary Arunsi.B, Jenova R, M.A.Majid, VLSI design of intelligent, Self- monitored and managed, Strip-free, Non- invasive device for Diabetes meiiitus Patients to improve Glycemic controle using IOT. Procedia Comp Sci 2019; 163:117-124. [DOI:10.1016/j.procs.2019.12.093]

4. Wilkins E, Atanasov P, Glucose monitoring: state of the art and future possibilities. J Med Eng Phy 1996; 18: 273-288. [DOI:10.1016/1350-4533(95)00046-1]

5. Yörük Ü, Yaykasli KO, Özhan H, Memisogullari R, Karabacak A, Bulur S, et al. Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyol Derg 2014; 14: 511-514. [DOI:10.5152/akd.2013.4932]

6. Silva TBC, Almeida PHRF, Araújo VE, Acurcio FA, Guerra Júnior AA, Godman B, et al. Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. Ther Adv Endocrinol Metab 2018;9:241-254. [DOI:10.1177/2042018818781414]

7. Rezaie F, Nezhadali M, Hedayati M; Association of adiponectin rs17300539 gene polymorphism with a nonalcoholic fatty liver disease in an Iranian population. Feyz 2018; 22: 379-86. [In Persian]

8. Yan Z, Bo Z,Caixia H. Omentin-A, Novel Adipokine in Respiratory Disease. Int J Mol Sci 2018; 19: 73. [DOI:10.3390/ijms19010073]

9. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest 2015; 21:57-74. [DOI:10.1515/hmbci-2014-0037]

10. As Habi A, Sadeghi M, Arab A, Hajianfar H. The association between omentin and diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab Syndr Obes 2019; 12: 1277-1286. [DOI:10.2147/DMSO.S206981]

11. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56:1655-61. [DOI:10.2337/db06-1506]

12. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068-83. [DOI:10.1016/S0140-6736(13)62154-6]

13. Diaz JJ, Ig Lewis's P. The role of novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148:293-300. [DOI:10.1530/eje.0.1480293]

14. Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci 2018;14:1483-1496. [DOI:10.7150/ijbs.27173]

15. Khoshi A, Bajestani MK, Shakeri H, Goodarzi G, Azizi F. Association of Omentin rs2274907 and FTO rs9939609 gene polymorphisms with insulin resistance in Iranian individuals with newly diagnosed type 2 diabetes. Lipids Health Dis 2019;18:142. [DOI:10.1186/s12944-019-1085-5]

16. Suliga E,, Kozieł D,, Cieśla E,, Rębak D, Wawszczak M, Adamus-Białek W, et al. Omentin rs2274907 gene polymorphism and the risk of metabolic syndrome: a preliminary report. Med Stud/Studia Medyczne 2018; 4: 267-275. [DOI:10.5114/ms.2018.80941]

17. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-61. [DOI:10.1152/ajpendo.00572.2004]

18. Ghatak S, Muthukumaran RB, Nachimuthu SK. A simple method of genomic DNA extraction from human samples for PCR-RFLP analysis. J Biomol Tech 2013;24:224-31. [DOI:10.7171/jbt.13-2404-001]

19. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402. [DOI:10.1016/j.jhep.2015.11.004]

20. Halabis M, Dziedzic M, Warchulinska J, Kaznowska-Bystryk I, Solski J. Omentin-a new adipokine with many roles to play. Curr Issues Pharm Med Sci 2015; 28:176-80. [DOI:10.1515/cipms-2015-0067]

21. Elsaid NH, Sadik NA, Ahmed NR, Fayez SE, Mohammed NAE. Serum omentin-1 levels in type 2 diabetic obese women in relation to glycemic control, insulin resistance and metabolic parameters. J Clin Transl Endocrinol 2018;13:14-19. [DOI:10.1016/j.jcte.2018.05.003]

22. Mrozikiewicz-Rakowska B, Sobczyk-Kopcioł A, Szymański K, Nehring P, Szatkowski P, Bartkowiak-Wieczorek J, et al. Role of the rs2274907 allelic variant of the ITLN1 gene in patients with diabetic foot. Pol Arch Intern Med 2017;127:319-327.

23. Zhang Q, Zhu L, Zheng M, Fan C, Li Y, Zhang D, et al. Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults. Ann Endocrinol (Paris) 2014;75:171-5. [DOI:10.1016/j.ando.2014.04.013]

24. Rebiya Nuli, Jiaoyu Shan, Bing Zhang, Rui Li, Yaqun Guan. Correlation study on gut microbiota and omentin-1 gene polymorphism in Uyghur newly diagnosed type 2 diabetes. Research Square 2020; 10:21203.

25. Yaykasli KO, Yaykasli E, Ataoglu S, Ozsahin M, Memisogullari R, Celebi E, et al. The frequency of omentin Val109Asp polymorphism and the serum level of omentin in patients with rheumatoid arthritis. Acta Medica Mediterranea 2013;29:521-6.

26. Schäffler A, Zeitoun M, Wobser H, Buechler C, Aslanidis C, Herfarth H. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovasc Diabetol 2007; 3:1475-2840-6-3. [DOI:10.1186/1475-2840-6-3]

27. Turan H, Yaykasli KO, Soguktas H, Yaykasli E, Aliagaoglu C, Erdem T, et al. Omentin serum levels and omentin gene Val109Asp polymorphism in patients with psoriasis. Int J Dermatol 2014;53:601-5. [DOI:10.1111/ijd.12306]

28. Yörük U, Yaykaşli KO, Özhan H, Memişoğullari R, Karabacak A, Bulur S, et al. Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyol Derg 2014;14:511-4. [DOI:10.5152/akd.2013.4932]

29. Boron D, Czerny B, Bartkowiak-Wieczorek J, Sieron D, Wolski H. Omentin polymorphism and its relations to bone mineral density in women. Arch Med Res 2015; 46:173-80. [DOI:10.1016/j.arcmed.2015.03.012]

30. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011;32:873-8. [DOI:10.1038/aps.2011.26]

31. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20:143-8. [DOI:10.1016/j.tcm.2010.12.002]

32. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996;19:1138-41. [DOI:10.2337/diacare.19.10.1138]

33. Abdelraouf Korany M, Sonbol A, Mohamed Elgouhary S. Omentin-1 and diabetic retinopathy in type 2 diabetic patients. Alexandria J Med 2018; 54:323-326. [DOI:10.1016/j.ajme.2018.04.003]

34. Vimaleswaran KS, Bodhini D, Jiang J, Ramya K, Mohan D, Shanthi Rani CS, et al. Circulating adiponectin mediates the association between omentin gene polymorphism and cardiometabolic health in Asian Indians. PLoS One 2021;16:e0238555. [DOI:10.1371/journal.pone.0238555]

35. Kohan L, Safarpur M, Abdollahi H. Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease. Mol Biol Res Commun 2016; 5:11-7.

36. Rathwa N, Patel R, Pramanik Palit S, Jadeja SD, Narwaria M, Ramachandran AV, et al. Circulatory Omentin-1 levels but not genetic variants influence the pathophysiology of Type 2 diabetes. Cytokine 2019; 119:144-51. [DOI:10.1016/j.cyto.2019.03.011]

37. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 1:15080. [DOI:10.1038/nrdp.2015.80]

38. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172: 367-79. [DOI:10.1503/cmaj.1040752]